Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12621462,MTD,Mucositis was the dose-limiting toxicity and the MTD was 60 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),mg,60,5056,DB01177,Idarubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],7.7,5057,DB01177,Idarubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],26.3,5058,DB01177,Idarubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],14.8,5059,DB01177,Idarubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],47.4,5060,DB01177,Idarubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],423.2,5061,DB01177,Idarubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],2581,5062,DB01177,Idarubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],732.8,5063,DB01177,Idarubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],4590,5064,DB01177,Idarubicin
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,28.6,5065,DB01177,Idarubicin
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,38.5,5066,DB01177,Idarubicin
,11721966,elimination half lives (t 1/2),"The elimination half lives (t 1/2) of IDA were 11.0 hours and 12.5 hours after administration of 12 and 15 mg/m2 IDA, respectively.",A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721966/),h,11.0,9206,DB01177,Idarubicin
,11721966,elimination half lives (t 1/2),"The elimination half lives (t 1/2) of IDA were 11.0 hours and 12.5 hours after administration of 12 and 15 mg/m2 IDA, respectively.",A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721966/),h,12.5,9207,DB01177,Idarubicin
,11721966,t 1/2,"IDAol had a very long t 1/2 (69.2 hours and 70.0 hours for 12 and 15 mg/m2, respectively).",A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721966/),h,69.2,9208,DB01177,Idarubicin
,11721966,t 1/2,"IDAol had a very long t 1/2 (69.2 hours and 70.0 hours for 12 and 15 mg/m2, respectively).",A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11721966/),h,70.0,9209,DB01177,Idarubicin
,3165708,maximal tolerated oral dose,The maximal tolerated oral dose of idarubicin was 40 mg/m2 per day.,Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),,40,35004,DB01177,Idarubicin
,3165708,terminal plasma half-life,"The medium terminal plasma half-life of idarubicin was 9.2 h (range, 6.4-25.5 h).",Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),h,9.2,35005,DB01177,Idarubicin
,3165708,concentration,"Among the five patients with acute nonlymphoblastic leukemia whose cells were tested for drug sensitivity in vitro, the idarubicin concentration resulting in 50% inhibition (IC50) of cluster and colony formation ranged from 1.6 x 10(-10) M to 5 x 10(-7) M.",Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),M,1.6 x 10(-10),35006,DB01177,Idarubicin
,3165708,50% inhibition (IC50),"Among the five patients with acute nonlymphoblastic leukemia whose cells were tested for drug sensitivity in vitro, the idarubicin concentration resulting in 50% inhibition (IC50) of cluster and colony formation ranged from 1.6 x 10(-10) M to 5 x 10(-7) M.",Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),M,1.6 x 10(-10),35007,DB01177,Idarubicin
,3165708,50% inhibition (IC50),"Among the five patients with acute nonlymphoblastic leukemia whose cells were tested for drug sensitivity in vitro, the idarubicin concentration resulting in 50% inhibition (IC50) of cluster and colony formation ranged from 1.6 x 10(-10) M to 5 x 10(-7) M.",Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),M,5 x 10(-7),35008,DB01177,Idarubicin
,6595240,elimination half-life,"The 13-dihydroderivative was present at higher and more prolonged levels than the parent compound, with an elimination half-life of about 40 hours.",Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595240/),h,40,35039,DB01177,Idarubicin
,3457647,Peak levels,Plasma levels of the reduced metabolite DMDRol were higher than those of the parent compound: Peak levels were 4-10 ng/ml for DMDR and 15-40 ng/ml for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [ml],4-10,51995,DB01177,Idarubicin
,3457647,Peak levels,Plasma levels of the reduced metabolite DMDRol were higher than those of the parent compound: Peak levels were 4-10 ng/ml for DMDR and 15-40 ng/ml for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [ml],15-40,51996,DB01177,Idarubicin
,3457647,area under the time-concentration curve (AUC),"The dose-corrected area under the time-concentration curve (AUC) was consequently higher for DMDRol (12.3-74.7, mean 32.6 vs 2.4-7.4, mean 4.6 ng/ml.mg for DMDR).",Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [mg·ml],32.6,51997,DB01177,Idarubicin
,3457647,area under the time-concentration curve (AUC),"The dose-corrected area under the time-concentration curve (AUC) was consequently higher for DMDRol (12.3-74.7, mean 32.6 vs 2.4-7.4, mean 4.6 ng/ml.mg for DMDR).",Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [mg·ml],4.6,51998,DB01177,Idarubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,13-36,51999,DB01177,Idarubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,23.7,52000,DB01177,Idarubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,30-81,52001,DB01177,Idarubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,58.9,52002,DB01177,Idarubicin
,2556012,cumulative dose,"The median cumulative dose was 110 mg/m2 (range: 50-1,100).",Phase II study of idarubicin in extensive-disease non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556012/),[mg] / [m2],110,52723,DB01177,Idarubicin
,3471367,T 1/2 alpha,"The serum levels of 4-DMDNR after a single i.v. bolus injection followed a triple exponential decay curve (T 1/2 alpha = 9.6 min, T 1/2 beta = 3.2 h and T 1/2 gamma = 34.7 h) and conformed to a three-compartment model.",Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471367/),min,9.6,56160,DB01177,Idarubicin
,3471367,T 1/2 beta,"The serum levels of 4-DMDNR after a single i.v. bolus injection followed a triple exponential decay curve (T 1/2 alpha = 9.6 min, T 1/2 beta = 3.2 h and T 1/2 gamma = 34.7 h) and conformed to a three-compartment model.",Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471367/),h,3.2,56161,DB01177,Idarubicin
,3471367,T 1/2 gamma,"The serum levels of 4-DMDNR after a single i.v. bolus injection followed a triple exponential decay curve (T 1/2 alpha = 9.6 min, T 1/2 beta = 3.2 h and T 1/2 gamma = 34.7 h) and conformed to a three-compartment model.",Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471367/),h,34.7,56162,DB01177,Idarubicin
,3471367,oral bioavailability,Comparison of the area under the curve (AUC) and urinary excretion for the oral and i.v. routes suggests an oral bioavailability of approximately 24%.,Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471367/),%,24,56163,DB01177,Idarubicin
,1998987,terminal half-life,"For different idarubicin doses in the phase I and bioavailability studies, the median values for the terminal half-life of idarubicin varied from 5.6 to 11.6 h.",Bioavailability and pharmacology of oral idarubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998987/),h,5.6 to 11.6,64600,DB01177,Idarubicin
,1998987,half-lives,"Idarubicinol was eliminated more slowly than was the parent compound, with median half-lives for different dose levels varying from 8 to 32.7 h.",Bioavailability and pharmacology of oral idarubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998987/),h,8 to 32.7,64601,DB01177,Idarubicin
,1998987,Oral bioavailability,"Oral bioavailability was determined by comparing oral idarubicin to i.v. drug with respect to the combined idarubicin and idarubicinol plasma AUCs, and it varied from 12%-49% (median, 29%).",Bioavailability and pharmacology of oral idarubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998987/),%,12%-49,64602,DB01177,Idarubicin
,1998987,Oral bioavailability,"Oral bioavailability was determined by comparing oral idarubicin to i.v. drug with respect to the combined idarubicin and idarubicinol plasma AUCs, and it varied from 12%-49% (median, 29%).",Bioavailability and pharmacology of oral idarubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998987/),%,29,64603,DB01177,Idarubicin
,1998987,Bioavailability,Bioavailability was essentially the same (30%) when whole-blood values were used.,Bioavailability and pharmacology of oral idarubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998987/),%,30,64604,DB01177,Idarubicin
less,1998987,Urinary excretion,Urinary excretion of the drug was less than 5% of the delivered dose by 96 h.,Bioavailability and pharmacology of oral idarubicin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998987/),%,5,64605,DB01177,Idarubicin
,3478310,plasma t1/2,Plasma levels of idarubicinal reached a peak of about 10 ng/ml within two hours then decreased very slowly with a plasma t1/2 of about 2.5 days.,Pharmacokinetic study of intravenous and oral idarubicin in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478310/),d,2.5,65466,DB01177,Idarubicin
,3471321,maximum tolerated dose,The maximum tolerated dose for patients with solid tumors was 15 mg/m2 course in 3 divided doses.,Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471321/),[mg] / [m],15,74270,DB01177,Idarubicin
,3471321,half-life,"The plasma clearance of idarubicin fits a 3-compartment model with a harmonic mean half-life of 2.4 min, 0.6 h, and 11.3 h for alpha, beta, and gamma phases, respectively.",Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471321/),min,2.4,74271,DB01177,Idarubicin
,3471321,half-life,"The plasma clearance of idarubicin fits a 3-compartment model with a harmonic mean half-life of 2.4 min, 0.6 h, and 11.3 h for alpha, beta, and gamma phases, respectively.",Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471321/),h,0.6,74272,DB01177,Idarubicin
,3471321,half-life,"The plasma clearance of idarubicin fits a 3-compartment model with a harmonic mean half-life of 2.4 min, 0.6 h, and 11.3 h for alpha, beta, and gamma phases, respectively.",Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471321/),h,11.3,74273,DB01177,Idarubicin
,3282579,elimination half-life,The elimination half-life of epirubicin or esorubicin is similar to that of doxorubicin (30 h) and the elimination half-life of unchanged idarubicin or pirarubicin is shorter (15-20 h).,[Pharmacokinetics of new anthracyclines]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282579/),h,30,83802,DB01177,Idarubicin
,3282579,elimination half-life,The elimination half-life of epirubicin or esorubicin is similar to that of doxorubicin (30 h) and the elimination half-life of unchanged idarubicin or pirarubicin is shorter (15-20 h).,[Pharmacokinetics of new anthracyclines]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282579/),h,15-20,83803,DB01177,Idarubicin
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],558.26,85527,DB01177,Idarubicin
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],315.44,85528,DB01177,Idarubicin
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2896.60,85529,DB01177,Idarubicin
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],1028.49,85530,DB01177,Idarubicin
,10456485,total body clearance (CL),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[l] / [(m)^2·h],83.51,85531,DB01177,Idarubicin
,10456485,total body clearance (CL),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[l] / [(m)^2·h],139.65,85532,DB01177,Idarubicin
,10456485,exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],331.29,85533,DB01177,Idarubicin
,10456485,exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],315.44,85534,DB01177,Idarubicin
,10456485,total body exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2030.32,85535,DB01177,Idarubicin
,10456485,total body exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],1028.49,85536,DB01177,Idarubicin
,10456485,AUC,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2030.32,85537,DB01177,Idarubicin
,10456485,AUC,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2896.60,85538,DB01177,Idarubicin
,22341684,recovery,"The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively.",HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),%,71,85979,DB01177,Idarubicin
,22341684,recovery,"The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively.",HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),%,78,85980,DB01177,Idarubicin
,22341684,recovery,"The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively.",HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),%,73,85981,DB01177,Idarubicin
,22341684,recovery,"The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively.",HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),%,80,85982,DB01177,Idarubicin
,22341684,limit of detection,The limit of detection of the method is 0.5 ng of Dox per injection (50 μL).,HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),ng,0.5,85983,DB01177,Idarubicin
,1605655,terminal half-lives (t1/2),The terminal half-lives (t1/2) of the drug in these patients were 6.40-15.10 hrs.,"[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605655/),h,6.40-15.10,88242,DB01177,Idarubicin
,1605655,t1/2,Its main metabolite idarubicinol remained longer in blood; t1/2 values were 43.46-51.01 hrs.,"[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605655/),h,43.46-51.01,88243,DB01177,Idarubicin
,1605655,plasma t1/2 alpha,"In 2-compartment multiple dose models, plasma t1/2 alpha and t1/2 beta of idarubicin were 0.25 +/- 0.13 hrs.","[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605655/),h,0.25,88244,DB01177,Idarubicin
,1605655,steady-state volume of distribution (Vdss),"The steady-state volume of distribution (Vdss) was 934.9 +/- 370.7 l/m2, and the plasma clearance was 82.3 +/- 29.7 l/hr/m2.","[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605655/),[l] / [m2],934.9,88245,DB01177,Idarubicin
,1605655,plasma clearance,"The steady-state volume of distribution (Vdss) was 934.9 +/- 370.7 l/m2, and the plasma clearance was 82.3 +/- 29.7 l/hr/m2.","[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605655/),[l] / [h·m2],82.3,88246,DB01177,Idarubicin
,1605655,cumulative urinary recovery rates,"Until 7 days after administration, the mean cumulative urinary recovery rates of idarubicin and idarubicinol were 2.04% and 11.53%, respectively, and 13.57% in total.","[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605655/),%,2.04,88247,DB01177,Idarubicin
,1605655,cumulative urinary recovery rates,"Until 7 days after administration, the mean cumulative urinary recovery rates of idarubicin and idarubicinol were 2.04% and 11.53%, respectively, and 13.57% in total.","[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605655/),%,11.53,88248,DB01177,Idarubicin
,1605655,cumulative urinary recovery rates,"Until 7 days after administration, the mean cumulative urinary recovery rates of idarubicin and idarubicinol were 2.04% and 11.53%, respectively, and 13.57% in total.","[A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605655/),%,13.57,88249,DB01177,Idarubicin
,3457779,maximum tolerated,"With this schedule, the maximum tolerated dose was 25 mg/m2 and leukopenia was again the dose-limiting toxicity.",Phase I study of oral idarubicin given with a weekly schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457779/),,25,94822,DB01177,Idarubicin
,3480399,half-life,Due to a protracted half-life (40 h) this compound progressively accumulated in plasma without the occurrence of peaks after the injections.,Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480399/),h,40,97790,DB01177,Idarubicin
,2369795,alpha half-life,Pharmacologic studies showed a mean alpha half-life of 1.6 +/- 0.3 h and a beta half-life of 39 +/- 8.4 h for idarubicin.,Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369795/),h,1.6,106217,DB01177,Idarubicin
,2369795,beta half-life,Pharmacologic studies showed a mean alpha half-life of 1.6 +/- 0.3 h and a beta half-life of 39 +/- 8.4 h for idarubicin.,Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369795/),h,39,106218,DB01177,Idarubicin
,10873078,MTD,"In conclusion, the MTD of this schedule is 10 mg/day and the DLTs are neutropenia and diarrhea.",Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873078/),,10,110284,DB01177,Idarubicin
,2731405,half-lives,"The half-lives of idarubicin and idarubicinol were 19 and 60 hours, respectively.",Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731405/),h,19,111494,DB01177,Idarubicin
,2731405,half-lives,"The half-lives of idarubicin and idarubicinol were 19 and 60 hours, respectively.",Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731405/),h,60,111495,DB01177,Idarubicin
,17256136,terminal half-life,"The mean terminal half-life measured for IDA in this group of patients (14.9 h) was not significantly different from the mean value observed after standard dose (13.9 h, P=0.72).",High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256136/),h,14.9,129332,DB01177,Idarubicin
,17256136,terminal half-life,"The mean terminal half-life measured for IDA in this group of patients (14.9 h) was not significantly different from the mean value observed after standard dose (13.9 h, P=0.72).",High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256136/),h,13.9,129333,DB01177,Idarubicin
,17256136,ol t1/2,"IDAol t1/2 was also similar after HD-IDA (46.2 h) and standard dose (39.4 h, P=0.79).",High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256136/),h,46.2,129334,DB01177,Idarubicin
,17256136,ol t1/2,"IDAol t1/2 was also similar after HD-IDA (46.2 h) and standard dose (39.4 h, P=0.79).",High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256136/),h,39.4,129335,DB01177,Idarubicin
,8916310,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was determined to be 15 mg/m2/d for 3 days (45 mg/m2 per course).,A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),[mg] / [d·m2],15,136190,DB01177,Idarubicin
,8916310,overall response rate,"When IDA was administered at this dosage or higher, there were three CRs and four partial responses, with an overall response rate of 26.9% in 26 assessable patients.",A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),%,26.9,136191,DB01177,Idarubicin
,8916310,terminal half-life (t1/2),The terminal half-life (t1/2) values for IDA were 6.4 to 15.1 hours in plasma and 8.09 to 16.34 hours in blood cells.,A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),h,6.4 to 15.1,136192,DB01177,Idarubicin
,8916310,terminal half-life (t1/2),The terminal half-life (t1/2) values for IDA were 6.4 to 15.1 hours in plasma and 8.09 to 16.34 hours in blood cells.,A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),h,8.09 to 16.34,136193,DB01177,Idarubicin
,8916310,t1/2,The t1/2 values for idarubicinol were much longer: 43.46 to 51.01 hours in plasma and 36.61 to 54.70 hours in blood cells.,A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),h,43.46 to 51.01,136194,DB01177,Idarubicin
,8916310,t1/2,The t1/2 values for idarubicinol were much longer: 43.46 to 51.01 hours in plasma and 36.61 to 54.70 hours in blood cells.,A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),h,36.61 to 54.70,136195,DB01177,Idarubicin
,8916310,plasma t1/2 alpha,"When two-compartment multiple-dose models were used, plasma t1/2 alpha and t1/2 beta values of IDA were 0.25 +/- 0.13 and 9.4 +/- 3.4 hours, respectively.",A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),h,0.25,136196,DB01177,Idarubicin
,8916310,t1/2 beta,"When two-compartment multiple-dose models were used, plasma t1/2 alpha and t1/2 beta values of IDA were 0.25 +/- 0.13 and 9.4 +/- 3.4 hours, respectively.",A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),h,9.4,136197,DB01177,Idarubicin
,8916310,steady-state volume of distribution (Vdss),"The steady-state volume of distribution (Vdss) was 934.9 +/- 370.7 L/m2, and the plasma clearance was 82.3 +/- 29.7 L/h/m2.",A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),[l] / [m2],934.9,136198,DB01177,Idarubicin
,8916310,plasma clearance,"The steady-state volume of distribution (Vdss) was 934.9 +/- 370.7 L/m2, and the plasma clearance was 82.3 +/- 29.7 L/h/m2.",A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),[l] / [h·m2],82.3,136199,DB01177,Idarubicin
,8916310,cumulative urinary recovery rates,The mean cumulative urinary recovery rates were 2.04% for IDA and 11.53% for idarubicinol up to 7 days.,A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),%,2.04,136200,DB01177,Idarubicin
,8916310,cumulative urinary recovery rates,The mean cumulative urinary recovery rates were 2.04% for IDA and 11.53% for idarubicinol up to 7 days.,A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916310/),%,11.53,136201,DB01177,Idarubicin
,9402748,overall response rate,Thirty-five patients (53%) achieved CR and 9 PR for an overall response rate of 67%.,Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),%,67,142609,DB01177,Idarubicin
,9402748,Overall survival,"Overall survival and disease free survival were 14 and 13 months, respectively.",Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),month,14,142610,DB01177,Idarubicin
,9402748,disease free survival,"Overall survival and disease free survival were 14 and 13 months, respectively.",Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),month,13,142611,DB01177,Idarubicin
,31541945,overall response rate,"The overall response rate was 60.9%, 43.5% achieved a complete remission (CR), and 17.4% achieved CR with incomplete count recovery.",Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31541945/),%,60.9,143054,DB01177,Idarubicin
,10582671,tumor:concurrent plasma ratio,The median tumor:concurrent plasma ratio of idarubicinol was 5.7 (range 1.7-18).,Penetration of idarubicin into malignant brain tumor tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582671/),,5.7,146835,DB01177,Idarubicin
,25311967,Time to reach 75% of the release plateau level,Time to reach 75% of the release plateau level was 37 minutes ± 6 for DC Bead DEE agents and 170 minutes ± 19 for ONCOZENE DEE agents both loaded with idarubicin 10 mg/mL.,Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311967/),min,37,147851,DB01177,Idarubicin
,25311967,Time to reach 75% of the release plateau level,Time to reach 75% of the release plateau level was 37 minutes ± 6 for DC Bead DEE agents and 170 minutes ± 19 for ONCOZENE DEE agents both loaded with idarubicin 10 mg/mL.,Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311967/),min,170,147852,DB01177,Idarubicin
,25311967,time to maximum concentration,"Median time to maximum concentration for idarubicin in patients was 10 minutes, and mean maximum concentration was 4.9 µg/L ± 1.7.",Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311967/),min,10,147853,DB01177,Idarubicin
,25311967,maximum concentration,"Median time to maximum concentration for idarubicin in patients was 10 minutes, and mean maximum concentration was 4.9 µg/L ± 1.7.",Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311967/),[μg] / [l],4.9,147854,DB01177,Idarubicin
,25311967,area under the concentration-time curve from 0-24 hours,Mean area under the concentration-time curve from 0-24 hours was equal to 29.5 µg.h/L ± 20.5.,Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25311967/),[h·μg] / [l],29.5,147855,DB01177,Idarubicin
,16497825,time to progression,The median time to progression was 3 months and the median overall survival was 17 months.,Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497825/),month,3,152559,DB01177,Idarubicin
,16497825,overall survival,The median time to progression was 3 months and the median overall survival was 17 months.,Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497825/),month,17,152560,DB01177,Idarubicin
,8491056,half-life (t1/2),"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),min,13,154775,DB01177,Idarubicin
,8491056,half-life (t1/2),"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),h,2.4,154776,DB01177,Idarubicin
,8491056,half-life (t1/2),"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),h,16,154777,DB01177,Idarubicin
,8491056,clearance,"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),[l] / [h·m2],60,154778,DB01177,Idarubicin
,8491056,volume of distribution at steady-state,"The pharmacokinetics of idarubicin follow a 2- or 3-compartment plasma disappearance with half-life (t1/2) values of 13 min, 2.4h and 16h, clearance approximately 60 L/h/m2 and volume of distribution at steady-state of 1,500 L/m2.",Clinical pharmacokinetics of idarubicin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),[l] / [m2],"1,500",154779,DB01177,Idarubicin
,8491056,elimination t1/2,Idarubicinol is characterised by a very long elimination t1/2 of 55h.,Clinical pharmacokinetics of idarubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),h,55,154780,DB01177,Idarubicin
>,8491056,ratio of meta,"The ratio of metabolite: parent drug area under the plasma concentration-time curve is often > 2 and is even higher after 2 or 3 daily injections of the drug, the normal drug protocol used in induction or consolidation treatments of acute leukaemias.",Clinical pharmacokinetics of idarubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),,2,154781,DB01177,Idarubicin
,8491056,bioavailability,"The bioavailability of idarubicin is 20 to 25%, but if the activity of idarubicinol is taken into account, it is effectively about 40%.",Clinical pharmacokinetics of idarubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),%,20 to 25,154782,DB01177,Idarubicin
,8491056,bioavailability,"The bioavailability of idarubicin is 20 to 25%, but if the activity of idarubicinol is taken into account, it is effectively about 40%.",Clinical pharmacokinetics of idarubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491056/),%,40,154783,DB01177,Idarubicin
,33316898,limit of detection (LOD),"The linearity was confirmed in the range of 0.1-50 ng/mL and 0.25-200 ng/mL, while the limit of detection (LOD) was 0.05 and 0.125 ng/mL in plasma and urine samples, respectively.",Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: An Application in Drug Monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33316898/),[ng] / [ml],0.05,157057,DB01177,Idarubicin
,33316898,limit of detection (LOD),"The linearity was confirmed in the range of 0.1-50 ng/mL and 0.25-200 ng/mL, while the limit of detection (LOD) was 0.05 and 0.125 ng/mL in plasma and urine samples, respectively.",Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: An Application in Drug Monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33316898/),[ng] / [ml],0.125,157058,DB01177,Idarubicin
,3459594,terminal half-life,"In nine patients who received DMDR IV the unchanged drug disappeared from the plasma biphasically with a mean terminal half-life of 27.0 +/- 5.5 h, an apparent volume of distribution of 63.9 +/- 12.61 kg-1, and a total clearance of 1.9 +/- 0.41 kg-1 h-1.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),h,27.0,162106,DB01177,Idarubicin
,3459594,apparent volume of distribution,"In nine patients who received DMDR IV the unchanged drug disappeared from the plasma biphasically with a mean terminal half-life of 27.0 +/- 5.5 h, an apparent volume of distribution of 63.9 +/- 12.61 kg-1, and a total clearance of 1.9 +/- 0.41 kg-1 h-1.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),1/[kg],63.9,162107,DB01177,Idarubicin
,3459594,total clearance,"In nine patients who received DMDR IV the unchanged drug disappeared from the plasma biphasically with a mean terminal half-life of 27.0 +/- 5.5 h, an apparent volume of distribution of 63.9 +/- 12.61 kg-1, and a total clearance of 1.9 +/- 0.41 kg-1 h-1.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),1/[h·kg],1.9,162108,DB01177,Idarubicin
,3459594,plasma half-life,"In comparison, in 19 studies the plasma half-life of DMDR given PO was 34.8 +/- 6.7 h, 2.3% +/- 1.3% was excreted in the urine in 24 h, and the maximum plasma drug concentration was reached in about 1 h.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),h,34.8,162109,DB01177,Idarubicin
,3459594,plasma half-life,"In comparison, in 19 studies the plasma half-life of DMDR given PO was 34.8 +/- 6.7 h, 2.3% +/- 1.3% was excreted in the urine in 24 h, and the maximum plasma drug concentration was reached in about 1 h.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),%,2.3,162110,DB01177,Idarubicin
,3459594,bioavailability,"The bioavailability of DMDR given PO was about 39% according to comparison of the areas under the plasma DMDR concentration versus time curves for the two routes, but 45% according to comparison of the 24-h cumulative urinary excretion rates.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),%,39,162111,DB01177,Idarubicin
,3459594,bioavailability,"The bioavailability of DMDR given PO was about 39% according to comparison of the areas under the plasma DMDR concentration versus time curves for the two routes, but 45% according to comparison of the 24-h cumulative urinary excretion rates.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),%,45,162112,DB01177,Idarubicin
,3459594,half-life,"In one patient with severe liver dysfunction following oral administration, the plasma DMDR half-life was 56.8 h, more than twice the average length.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),h,56.8,162113,DB01177,Idarubicin
,3459594,plasma half-life,"The plasma half-life of DMDR-ol was 72.5 +/- 24.7 h, or 35.7 +/- 7.4 when DMDR was administered IV or PO.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),h,72.5,162114,DB01177,Idarubicin
,3459594,plasma half-life,"The plasma half-life of DMDR-ol was 72.5 +/- 24.7 h, or 35.7 +/- 7.4 when DMDR was administered IV or PO.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),,35.7,162115,DB01177,Idarubicin
,3459594,cumulative urinary excretion,"Moreover, the 24 h cumulative urinary excretion of DMDR-ol as a percentage of the dose of DMDR administered was 7.8 following IV and 7.4 following PO administration.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),,7.8,162116,DB01177,Idarubicin
,3459594,cumulative urinary excretion,"Moreover, the 24 h cumulative urinary excretion of DMDR-ol as a percentage of the dose of DMDR administered was 7.8 following IV and 7.4 following PO administration.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),,7.4,162117,DB01177,Idarubicin
,11808862,clearance (CL,"The basic pharmacokinetic parameters clearance (CL = 27.0 ml min(-1)), mean disposition residence time (MDRT = 519.2 min), and volume of distribution at steady state (Vss = 12.51) were estimated for IDA.",Pharmacokinetics and toxicity of idarubicin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808862/),[ml] / [min],27.0,163123,DB01177,Idarubicin
,11808862,mean disposition residence time (MDRT,"The basic pharmacokinetic parameters clearance (CL = 27.0 ml min(-1)), mean disposition residence time (MDRT = 519.2 min), and volume of distribution at steady state (Vss = 12.51) were estimated for IDA.",Pharmacokinetics and toxicity of idarubicin in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808862/),min,519.2,163124,DB01177,Idarubicin
,11808862,volume of distribution at steady state (Vss,"The basic pharmacokinetic parameters clearance (CL = 27.0 ml min(-1)), mean disposition residence time (MDRT = 519.2 min), and volume of distribution at steady state (Vss = 12.51) were estimated for IDA.",Pharmacokinetics and toxicity of idarubicin in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808862/),,12.51,163125,DB01177,Idarubicin
,11808862,mean residence time (MRT),The mean residence time (MRT) of the generated IDOL was 2982.5 min.,Pharmacokinetics and toxicity of idarubicin in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808862/),min,2982.5,163126,DB01177,Idarubicin
,11808862,survival time,The mean survival time of 13.3 days is attributed to a severe myelosuppression.,Pharmacokinetics and toxicity of idarubicin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808862/),d,13.3,163127,DB01177,Idarubicin
,7786781,half-life,"The apparent terminal half-life of IDAol was significantly longer in the elderly than in the younger patients (mean half-life 59.7 h versus 41.4 h, P < 0.05).",Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786781/),h,59.7,164234,DB01177,Idarubicin
,7786781,half-life,"The apparent terminal half-life of IDAol was significantly longer in the elderly than in the younger patients (mean half-life 59.7 h versus 41.4 h, P < 0.05).",Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786781/),h,41.4,164235,DB01177,Idarubicin
,8618451,terminal half-life,The average terminal half-life was 30.5h for idarubicin and 66.9 h for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),h,30.5,174570,DB01177,Idarubicin
,8618451,terminal half-life,The average terminal half-life was 30.5h for idarubicin and 66.9 h for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),h,66.9,174571,DB01177,Idarubicin
,8618451,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4 - 445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),[h·ng] / [ml],25.7 to 114,174572,DB01177,Idarubicin
,8618451,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4 - 445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),[h·ng] / [ml],58.1,174573,DB01177,Idarubicin
,8618451,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4 - 445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618451/),[h·ng] / [ml],287.3,174574,DB01177,Idarubicin
,10029808,terminal half-life,"Daunorubicin elimination from plasma was triphasic with a terminal half-life of 5.9 +/- 1.8 hours, area under the concentration-time curve (AUC) 22.5 +/- 9.2 mumol/L.min, and clearance 2790 +/- 960 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,5.9,179988,DB01177,Idarubicin
,10029808,area under the concentration-time curve (AUC),"Daunorubicin elimination from plasma was triphasic with a terminal half-life of 5.9 +/- 1.8 hours, area under the concentration-time curve (AUC) 22.5 +/- 9.2 mumol/L.min, and clearance 2790 +/- 960 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],22.5,179989,DB01177,Idarubicin
,10029808,clearance,"Daunorubicin elimination from plasma was triphasic with a terminal half-life of 5.9 +/- 1.8 hours, area under the concentration-time curve (AUC) 22.5 +/- 9.2 mumol/L.min, and clearance 2790 +/- 960 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[ml] / [m2·min],2790,179990,DB01177,Idarubicin
,10029808,terminal half-life,Daunorubicinol elimination was biphasic with a terminal half-life 10.2 +/- 2.3 hours and an AUC 74.5 +/- 5.3 mumol/L.min.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,10.2,179991,DB01177,Idarubicin
,10029808,AUC,Daunorubicinol elimination was biphasic with a terminal half-life 10.2 +/- 2.3 hours and an AUC 74.5 +/- 5.3 mumol/L.min.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],74.5,179992,DB01177,Idarubicin
,10029808,terminal half-life,"Idarubicin elimination was triphasic with terminal half-life of 12.3 +/- 11.4 hours, a AUC 10.8 +/- 3.7 mumol/L.min, and clearance 1650 +/- 610 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,12.3,179993,DB01177,Idarubicin
,10029808,AUC,"Idarubicin elimination was triphasic with terminal half-life of 12.3 +/- 11.4 hours, a AUC 10.8 +/- 3.7 mumol/L.min, and clearance 1650 +/- 610 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],10.8,179994,DB01177,Idarubicin
,10029808,clearance,"Idarubicin elimination was triphasic with terminal half-life of 12.3 +/- 11.4 hours, a AUC 10.8 +/- 3.7 mumol/L.min, and clearance 1650 +/- 610 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[ml] / [m2·min],1650,179995,DB01177,Idarubicin
,10029808,terminal half-life,Idarubicinol elimination was biphasic with a terminal half-life 28.7 +/- 4.2 hours and AUC 67 +/- 9.8 mumol/L.min.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,28.7,179996,DB01177,Idarubicin
,10029808,AUC,Idarubicinol elimination was biphasic with a terminal half-life 28.7 +/- 4.2 hours and AUC 67 +/- 9.8 mumol/L.min.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],67,179997,DB01177,Idarubicin
,10029808,CSF to plasma concentration ratio,The CSF to plasma concentration ratio at that time point was 8% in 1 animal and 15% in the other.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),%,8,179998,DB01177,Idarubicin
,10029808,CSF to plasma concentration ratio,The CSF to plasma concentration ratio at that time point was 8% in 1 animal and 15% in the other.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),%,15,179999,DB01177,Idarubicin
,10029808,CSF to plasma concentration ratio,The CSF to plasma concentration ratio at corresponding time points was 1.9 +/- 0.6%.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),%,1.9,180000,DB01177,Idarubicin
,10029808,terminal half-life,"The terminal half-life of daunorubicinol in CSF was 8.8 +/- 1.3 hours, the AUC was 1.8 +/- 1.5 mumol/L.min, and the AUCCSF to AUCplasma ratio was 2.4 +/- 1.9%.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,8.8,180001,DB01177,Idarubicin
,10029808,AUC,"The terminal half-life of daunorubicinol in CSF was 8.8 +/- 1.3 hours, the AUC was 1.8 +/- 1.5 mumol/L.min, and the AUCCSF to AUCplasma ratio was 2.4 +/- 1.9%.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],1.8,180002,DB01177,Idarubicin
,10029808,AUCCSF to AUCplasma ratio,"The terminal half-life of daunorubicinol in CSF was 8.8 +/- 1.3 hours, the AUC was 1.8 +/- 1.5 mumol/L.min, and the AUCCSF to AUCplasma ratio was 2.4 +/- 1.9%.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),%,2.4,180003,DB01177,Idarubicin
,11997119,AUC(0-4h),"The mean AUC(0-4h) for free IDA was 0.030 micromole h/ml as compared to 1.38 micromole h/ml determined for the DSPC:DSPE-PEG(2000) formulation, a 45-fold increase, demonstrating that IDA was retained better in cholesterol-free compared to cholesterol-containing liposomes.",Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11997119/),[h·μmole] / [ml],0.030,195662,DB01177,Idarubicin
,11997119,AUC(0-4h),"The mean AUC(0-4h) for free IDA was 0.030 micromole h/ml as compared to 1.38 micromole h/ml determined for the DSPC:DSPE-PEG(2000) formulation, a 45-fold increase, demonstrating that IDA was retained better in cholesterol-free compared to cholesterol-containing liposomes.",Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11997119/),[h·μmole] / [ml],1.38,195663,DB01177,Idarubicin
,9708950,response rate,"The response rate for patients with relapsed high grade astrocytoma was 15% (95% confidence interval, 3.3-40%).",A Phase II clinical trial of idarubicin administered to children with relapsed brain tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9708950/),%,15,198435,DB01177,Idarubicin
,1592361,total plasma clearance,"The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39.0 L/h/m2 for idarubicin versus 38.6 for daunorubicin), total volume of distribution (1756 versus 1725 L/m2) and elimination half-life (42.7 versus 47.4 h).",Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1592361/),[l] / [h·m2],39.0,200309,DB01177,Idarubicin
,1592361,total plasma clearance,"The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39.0 L/h/m2 for idarubicin versus 38.6 for daunorubicin), total volume of distribution (1756 versus 1725 L/m2) and elimination half-life (42.7 versus 47.4 h).",Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1592361/),,38.6,200310,DB01177,Idarubicin
,1592361,total volume of distribution,"The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39.0 L/h/m2 for idarubicin versus 38.6 for daunorubicin), total volume of distribution (1756 versus 1725 L/m2) and elimination half-life (42.7 versus 47.4 h).",Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1592361/),[l] / [m2],1756,200311,DB01177,Idarubicin
,1592361,total volume of distribution,"The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39.0 L/h/m2 for idarubicin versus 38.6 for daunorubicin), total volume of distribution (1756 versus 1725 L/m2) and elimination half-life (42.7 versus 47.4 h).",Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1592361/),[l] / [m2],1725,200312,DB01177,Idarubicin
,1592361,elimination half-life,"The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39.0 L/h/m2 for idarubicin versus 38.6 for daunorubicin), total volume of distribution (1756 versus 1725 L/m2) and elimination half-life (42.7 versus 47.4 h).",Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1592361/),h,42.7,200313,DB01177,Idarubicin
,1592361,elimination half-life,"The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39.0 L/h/m2 for idarubicin versus 38.6 for daunorubicin), total volume of distribution (1756 versus 1725 L/m2) and elimination half-life (42.7 versus 47.4 h).",Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1592361/),h,47.4,200314,DB01177,Idarubicin
,1592361,elimination half-life,The elimination half-life of idarubicinol was two times higher than that of daunorubicinol (80.7 versus 37.3 h) which provided an AUC ratio metabolite/parent drug higher for idarubicin than for daunorubicin.,Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1592361/),h,80.7,200315,DB01177,Idarubicin
,1592361,elimination half-life,The elimination half-life of idarubicinol was two times higher than that of daunorubicinol (80.7 versus 37.3 h) which provided an AUC ratio metabolite/parent drug higher for idarubicin than for daunorubicin.,Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1592361/),h,37.3,200316,DB01177,Idarubicin
,24738629,MTD,The calculated MTD of idarubicin was 10 mg.,Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738629/),mg,10,201907,DB01177,Idarubicin
,24738629,objective response rate,"At 2 months, the objective response rate was 52% (complete response, 28%, and partial response, 24%) by modified Response Evaluation Criteria in Solid Tumours.",Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738629/),%,52,201908,DB01177,Idarubicin
,24738629,time to progression,The median time to progression was 12.1 months (95% CI 7.4 months--not reached); the median overall survival was 24.5 months (95% CI 14.7 months--not reached).,Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738629/),month,12.1,201909,DB01177,Idarubicin
,24738629,overall survival,The median time to progression was 12.1 months (95% CI 7.4 months--not reached); the median overall survival was 24.5 months (95% CI 14.7 months--not reached).,Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738629/),month,24.5,201910,DB01177,Idarubicin
,26060065,Cmax,"After TACE, mean idarubicin Cmax and AUC0-24h were 12.5 ± 9.4 ng/mL and 52 ± 16 ng/mL*h.",Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26060065/),[ng] / [ml],12.5,203352,DB01177,Idarubicin
,26060065,AUC0-24h,"After TACE, mean idarubicin Cmax and AUC0-24h were 12.5 ± 9.4 ng/mL and 52 ± 16 ng/mL*h.",Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26060065/),[ng] / [h·ml],52,203353,DB01177,Idarubicin
,2179640,half-life,"Due to its protracted half-life (64 hr in this study), this metabolite progressively accumulated and the ratio of the areas under the curve (0-24) idarubicinol/idarubicin increased from day to day.",Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2179640/),h,64,206252,DB01177,Idarubicin
,2179640,bioavailability,"By comparison to results obtained after i.v. administration of the drug in another study, the bioavailability of idarubicin alone can be estimated to about 21%, whereas the bioavailability of the sum idarubicin + idarubicinol is about 41%.",Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2179640/),%,21,206253,DB01177,Idarubicin
,2179640,bioavailability,"By comparison to results obtained after i.v. administration of the drug in another study, the bioavailability of idarubicin alone can be estimated to about 21%, whereas the bioavailability of the sum idarubicin + idarubicinol is about 41%.",Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2179640/),%,41,206254,DB01177,Idarubicin
,15661261,MTD,The MTD of idarubicin in this combination was 8 mg/(m(2) day) with a DLT of oral mucositis.,"A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[mg] / [d·m(2)],8,208630,DB01177,Idarubicin
,15661261,complete remission rate,"The complete remission rate (on an intent-to-treat basis) for this regimen was 33%, with a median duration of 6 months.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),%,33,208631,DB01177,Idarubicin
,15661261,clearance,"The clearance of idarubicin was 140 +/- 200 and 181 +/- 94.3 l/h for idarubicin alone and with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[l] / [h],140,208632,DB01177,Idarubicin
,15661261,clearance,"The clearance of idarubicin was 140 +/- 200 and 181 +/- 94.3 l/h for idarubicin alone and with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[l] / [h],181,208633,DB01177,Idarubicin
,15661261,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 423 +/- 443 and 337 +/- 394 l for idarubicin alone and in combination with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),l,423,208634,DB01177,Idarubicin
,15661261,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 423 +/- 443 and 337 +/- 394 l for idarubicin alone and in combination with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),l,337,208635,DB01177,Idarubicin
,18316568,total body clearance,"Pharmacokinetic studies revealed that the total body clearance of bortezomib decreased significantly (P < 0.01, N = 26) between the first (mean +/- SD, 41.9 +/- 17.1 L/h/m(2)) and third (18.4 +/- 7.0 L/h/m(2)) doses.",Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316568/),[h·l] / [m(2],41.9,215866,DB01177,Idarubicin
,18316568,total body clearance,"Pharmacokinetic studies revealed that the total body clearance of bortezomib decreased significantly (P < 0.01, N = 26) between the first (mean +/- SD, 41.9 +/- 17.1 L/h/m(2)) and third (18.4 +/- 7.0 L/h/m(2)) doses.",Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316568/),[h·l] / [m(2],18.4,215867,DB01177,Idarubicin
,2311174,bioavailability,"Nine of them also received an i.v. dose, and the bioavailability of the oral dose ranged between 9% and 39%.",Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311174/),%,9,218739,DB01177,Idarubicin
,2311174,bioavailability,"Nine of them also received an i.v. dose, and the bioavailability of the oral dose ranged between 9% and 39%.",Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311174/),%,39,218740,DB01177,Idarubicin
,29427728,MTD,The calculated MTD of idarubicin was 20 mg.,Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427728/),mg,20,218961,DB01177,Idarubicin
,29427728,objective response rate,"One month after the second session, the objective response rate was 29% (complete response, 0%; partial response, 29%) based on modified Response Evaluation Criteria In Solid Tumours.",Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427728/),%,29,218962,DB01177,Idarubicin
,29427728,time to progression,The median time to progression was 5.4 months [95% confidence limit (CI) 3.0-14.6 months] and median overall survival was 20.6 months (95% CI 5.7-28.7 months).,Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427728/),month,5.4,218963,DB01177,Idarubicin
,29427728,overall survival,The median time to progression was 5.4 months [95% confidence limit (CI) 3.0-14.6 months] and median overall survival was 20.6 months (95% CI 5.7-28.7 months).,Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427728/),month,20.6,218964,DB01177,Idarubicin
,29427728,MTD,The MTD of idarubicin was 20 mg after two chemolipiodolisation sessions.,Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427728/),mg,20,218965,DB01177,Idarubicin
,2208112,terminal half-life,"The mean terminal half-life, total body clearance, and steady state volume of distribution were 17.6 h, 679 ml/min/m2, and 562 l/m2, respectively.",Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208112/),h,17.6,219249,DB01177,Idarubicin
,2208112,total body clearance,"The mean terminal half-life, total body clearance, and steady state volume of distribution were 17.6 h, 679 ml/min/m2, and 562 l/m2, respectively.",Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208112/),[ml] / [m2·min],679,219250,DB01177,Idarubicin
,2208112,steady state volume of distribution,"The mean terminal half-life, total body clearance, and steady state volume of distribution were 17.6 h, 679 ml/min/m2, and 562 l/m2, respectively.",Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208112/),[l] / [m2],562,219251,DB01177,Idarubicin
,2208112,terminal half-life,Idarubicinol elimination was prolonged compared to that of the parent drug with a terminal half-life of 56.8 h.,Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208112/),h,56.8,219252,DB01177,Idarubicin
,2208112,Urinary recoveries,"Urinary recoveries (48 h) of idarubicin and idarubicinol after a single dose of idarubicin were 2.4 and 10.1%, respectively.",Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208112/),%,2.4,219253,DB01177,Idarubicin
,2208112,Urinary recoveries,"Urinary recoveries (48 h) of idarubicin and idarubicinol after a single dose of idarubicin were 2.4 and 10.1%, respectively.",Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208112/),%,10.1,219254,DB01177,Idarubicin
,2208112,Concentrations,Concentrations in the 20 samples varied from 0.22-1.05 ng/ml with a mean value of 0.51 ng/ml.,Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208112/),[ng] / [ml],0.51,219255,DB01177,Idarubicin
,9118470,Clearance (CL),"Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1].",Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118470/),[ml] / [min],221.7,223436,DB01177,Idarubicin
,9118470,CLD,"Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1].",Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118470/),[ml] / [min],248.3,223437,DB01177,Idarubicin
,9118470,steady-state volume of distribution (Vss),"Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1].",Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118470/),,24 1,223438,DB01177,Idarubicin
,3855696,time to CR,"All remissions were induced with one course of treatment with a median time to CR of 28 days (range, 22 to 40 days).",Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855696/),d,28,241222,DB01177,Idarubicin
,10783832,viability,"After 48 hours of total incubation, the viability of HL-60 cells was 56.88% with profile 1 (50 ng/ml idarubicin for 2 hours) and 83.00% with profile 2 (4.25 ng/ml for 24 hours).",Induction of apoptosis by idarubicin: how important is the plasma peak? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10783832/),%,56.88,248062,DB01177,Idarubicin
,10783832,viability,"After 48 hours of total incubation, the viability of HL-60 cells was 56.88% with profile 1 (50 ng/ml idarubicin for 2 hours) and 83.00% with profile 2 (4.25 ng/ml for 24 hours).",Induction of apoptosis by idarubicin: how important is the plasma peak? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10783832/),%,83.00,248063,DB01177,Idarubicin
,1643700,plasma clearance,"Analysis of variance indicated a significant correlation between IDA plasma clearance and creatinine clearance; it was also found that IDA plasma clearance was lower in patients whose creatinine clearance was less than 60 ml/min [group N, 122.8 +/- 44.0 l/h; group L, 104.4 +/- 27.7 l/h (P = 0.58) vs group R, 83.4 +/- 18.3 l/h (P = 0.037)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),[l] / [h],122.8,248280,DB01177,Idarubicin
,1643700,plasma clearance,"Analysis of variance indicated a significant correlation between IDA plasma clearance and creatinine clearance; it was also found that IDA plasma clearance was lower in patients whose creatinine clearance was less than 60 ml/min [group N, 122.8 +/- 44.0 l/h; group L, 104.4 +/- 27.7 l/h (P = 0.58) vs group R, 83.4 +/- 18.3 l/h (P = 0.037)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),[l] / [h],104.4,248281,DB01177,Idarubicin
,1643700,plasma clearance,"Analysis of variance indicated a significant correlation between IDA plasma clearance and creatinine clearance; it was also found that IDA plasma clearance was lower in patients whose creatinine clearance was less than 60 ml/min [group N, 122.8 +/- 44.0 l/h; group L, 104.4 +/- 27.7 l/h (P = 0.58) vs group R, 83.4 +/- 18.3 l/h (P = 0.037)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),[l] / [h],83.4,248282,DB01177,Idarubicin
,1643700,MRT,"The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63.6 +/- 10.8 h; group L, 69.9 +/- 10.2 h (P = 0.27) vs group R, 83.2 +/- 10.9 h (P = 0.025) and t1/2 gamma: group N, 41.3 +/- 10.1 h; group L, 47.0 +/- 7.4 h (P = 0.31) vs group R, 55.8 +/- 8.2 h (P = 0.025)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),h,63.6,248283,DB01177,Idarubicin
,1643700,MRT,"The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63.6 +/- 10.8 h; group L, 69.9 +/- 10.2 h (P = 0.27) vs group R, 83.2 +/- 10.9 h (P = 0.025) and t1/2 gamma: group N, 41.3 +/- 10.1 h; group L, 47.0 +/- 7.4 h (P = 0.31) vs group R, 55.8 +/- 8.2 h (P = 0.025)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),h,69.9,248284,DB01177,Idarubicin
,1643700,MRT,"The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63.6 +/- 10.8 h; group L, 69.9 +/- 10.2 h (P = 0.27) vs group R, 83.2 +/- 10.9 h (P = 0.025) and t1/2 gamma: group N, 41.3 +/- 10.1 h; group L, 47.0 +/- 7.4 h (P = 0.31) vs group R, 55.8 +/- 8.2 h (P = 0.025)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),h,83.2,248285,DB01177,Idarubicin
,1643700,t1/2 gamma,"The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63.6 +/- 10.8 h; group L, 69.9 +/- 10.2 h (P = 0.27) vs group R, 83.2 +/- 10.9 h (P = 0.025) and t1/2 gamma: group N, 41.3 +/- 10.1 h; group L, 47.0 +/- 7.4 h (P = 0.31) vs group R, 55.8 +/- 8.2 h (P = 0.025)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),h,41.3,248286,DB01177,Idarubicin
,1643700,t1/2 gamma,"The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63.6 +/- 10.8 h; group L, 69.9 +/- 10.2 h (P = 0.27) vs group R, 83.2 +/- 10.9 h (P = 0.025) and t1/2 gamma: group N, 41.3 +/- 10.1 h; group L, 47.0 +/- 7.4 h (P = 0.31) vs group R, 55.8 +/- 8.2 h (P = 0.025)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),h,47.0,248287,DB01177,Idarubicin
,1643700,t1/2 gamma,"The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63.6 +/- 10.8 h; group L, 69.9 +/- 10.2 h (P = 0.27) vs group R, 83.2 +/- 10.9 h (P = 0.025) and t1/2 gamma: group N, 41.3 +/- 10.1 h; group L, 47.0 +/- 7.4 h (P = 0.31) vs group R, 55.8 +/- 8.2 h (P = 0.025)].",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),h,55.8,248288,DB01177,Idarubicin
,1643700,AUC,"The AUC of IDAol was greater after oral administration than after i.v. treatment in proportion to the AUC of IDA (i.v.: AUC-IDAol/AUC-IDA, 2.4-18.9; p.o.: AUC-IDAol/AUC-IDA, 4.1-21.4).",Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643700/),,4,248289,DB01177,Idarubicin
,22404399,MTD,The MTD in dogs > 15 kg body weight was 22 mg/m(2) .,Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404399/),[mg] / [m(2],22,257631,DB01177,Idarubicin
,3465490,peak plasma D-DNM concentrations,"After bolus injection, peak plasma D-DNM concentrations were about 50 mg/ml.",Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465490/),[mg] / [ml],50,267678,DB01177,Idarubicin
,3465490,plasma t1/2s,D-DNM plasma t1/2s were 0.4 +/- 0.3 hours (T1/2 alpha) and 16.4 +/- 4.7 hours (T1/2 beta).,Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465490/),h,0.4,267679,DB01177,Idarubicin
,3465490,T1/2 beta,D-DNM plasma t1/2s were 0.4 +/- 0.3 hours (T1/2 alpha) and 16.4 +/- 4.7 hours (T1/2 beta).,Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465490/),h,16.4,267680,DB01177,Idarubicin
,3465490,cellular t1/2 times,"D-DNMol concentrations increased more slowly and accumulated on subsequent treatment days in cells and plasma; D-DNM and D-DNMol cellular t1/2 times were 42 and 72 hours, respectively.",Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465490/),h,42,267681,DB01177,Idarubicin
,3465490,cellular t1/2 times,"D-DNMol concentrations increased more slowly and accumulated on subsequent treatment days in cells and plasma; D-DNM and D-DNMol cellular t1/2 times were 42 and 72 hours, respectively.",Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465490/),h,72,267682,DB01177,Idarubicin
,3471265,terminal half-life,"Pharmacokinetic parameters calculated for the intravenous plasma drug concentration, time data revealed a terminal half-life of 12.9 +/- 6.0 h (mean +/- s.d.), clearance 98.7 +/- 47.3 1 h-1 m-2 and volume of distribution 1533 +/- 536 1 m-2.",Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471265/),h,12.9,274125,DB01177,Idarubicin
,3471265,clearance,"Pharmacokinetic parameters calculated for the intravenous plasma drug concentration, time data revealed a terminal half-life of 12.9 +/- 6.0 h (mean +/- s.d.), clearance 98.7 +/- 47.3 1 h-1 m-2 and volume of distribution 1533 +/- 536 1 m-2.",Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471265/),[1] / [(m)^2·h],98.7,274126,DB01177,Idarubicin
,3471265,volume of distribution,"Pharmacokinetic parameters calculated for the intravenous plasma drug concentration, time data revealed a terminal half-life of 12.9 +/- 6.0 h (mean +/- s.d.), clearance 98.7 +/- 47.3 1 h-1 m-2 and volume of distribution 1533 +/- 536 1 m-2.",Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471265/),[1] / [(m)^2],1533,274127,DB01177,Idarubicin
,3471265,Bioavailability,Bioavailability of oral idarubicin was 0.29 +/- 0.20 (mean +/- s.d.).,Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471265/),,0.29,274128,DB01177,Idarubicin
,3471265,half-life,The mean half-life of idarubicinol was not significantly different after i.v. (63.1 +/- 28.2 h) and oral (45.8 +/- 16.0 h) administration.,Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471265/),h,63.1,274129,DB01177,Idarubicin
,3471265,half-life,The mean half-life of idarubicinol was not significantly different after i.v. (63.1 +/- 28.2 h) and oral (45.8 +/- 16.0 h) administration.,Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471265/),h,45.8,274130,DB01177,Idarubicin
,9436933,terminal half-life,The average terminal half-life was 30.5 h for idarubicin and 66.9 h for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9436933/),h,30.5,274244,DB01177,Idarubicin
,9436933,terminal half-life,The average terminal half-life was 30.5 h for idarubicin and 66.9 h for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9436933/),h,66.9,274245,DB01177,Idarubicin
,9436933,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4-445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9436933/),[h·ng] / [ml],25.7 to 114,274246,DB01177,Idarubicin
,9436933,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4-445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9436933/),[h·ng] / [ml],58.1,274247,DB01177,Idarubicin
,9436933,AUC,The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4-445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol.,Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9436933/),[h·ng] / [ml],287.3,274248,DB01177,Idarubicin
